The rates of population-based screening and diagnosis of breast, cervical, and colorectal cancer in the USA in 2021 remained below those reported before the COVID-19 pandemic, researchers caution in JAMA Oncology.
A systematic review and meta-analysis has identified global decreases in breast, cervical, and colorectal cancer screening during the early phase of the COVID-19 pandemic.
Breast, prostate, and colorectal cancer screening rates declined sharply during the initial months of the COVID-19 pandemic in the USA, and while they subsequently recovered, a large deficit remains, study findings indicate.